Topically Applied Epsilon-Aminocaproic Acid Reduces Blood Loss and Length of Hospital Stay After Total Knee Arthroplasty

摘要

Perioperative blood loss after total knee arthroplasty (TKA) affects postoperative recovery. Tranexamic acid is safe and efficient in reducing blood loss without increasing thromboembolic events. Epsilon-aminocaproic acid (e-ACA) is less expensive than and as safe as tranexamic acid. Its efficiency when locally applied in TKA is unknown. The authors retrospectively followed 240 consecutive patients treated by 1 surgeon with TKA from January 2012 to August 2016. From January 2013 to May 2015, the authors topically applied 5 g of e-ACA to the open wound after tourniquet release and before closure (e-ACA-after-tourniquet-release group). From August 2015 to August 2016, the authors topically applied 5 g of e-ACA intraoperatively to the open wound 3 minutes before tourniquet release (e-ACA-before-tourniquet-release group). The last 80 patients not receiving e-ACA (control group), the 80 patients in the e-ACA-after-tourniquet-release group, and the 80 patients in the e-ACA-before-tourniquet-release group were compared regarding blood loss, treatment costs, and thromboembolic complications. The mean +/- SD calculated blood loss was 1478.8 +/- 367.1 mL for the control group, 1424.0 +/- 249.3 mL for the e-ACA-after-tourniquet-release group, and 1052.3 +/- 419.1 mL for the e-ACA-before-tourniquet-release group (P.05). Using e-ACA before tourniquet release reduced the length of hospital stay by 0.7 days (P.05) compared with not using e-ACA, leading to cost savings of $1547.37 per patient. One patient in the e-ACA-before-tourniquet-release group and 1 patient in the control group developed a venous thromboembolism in the postoperative period. Epsilon-aminocaproic acid significantly reduces blood loss after TKA when topically applied before tourniquet release. Its application reduced costs by decreasing the length of hospital stay and did not increase thromboembolic events.